Business Context and Reporting Period
This Form 8-K Current Report was filed by Oramed Pharmaceuticals Inc. on July 18, 2017. The report discloses significant changes in the Company's executive leadership, specifically the departure of the Chief Financial Officer and the appointment of a successor.
Key Financial Metrics
The filing does not provide revenue, profit, cash flow, margin, debt, or liquidity metrics. The document focuses exclusively on personnel changes and associated compensation terms.
Material Changes
- Departure: Yifat Zommer resigned as Chief Financial Officer, Treasurer, and Secretary effective August 1, 2017, citing personal reasons.
- Appointment: Hilla Eisenberg was appointed to succeed Ms. Zommer in all three roles, effective August 1, 2017.
- Background: Ms. Eisenberg previously served as the Company's Finance Manager (March 2016–July 2017) and holds a CPA license in Israel with prior experience at PricewaterhouseCoopers.
Compensation and Employment Terms
Ms. Eisenberg's employment is governed by an amended and restated agreement with Oramed Ltd. (the Company's Israeli subsidiary). Key terms include:
- Salary: Gross monthly salary of NIS 34,000.
- Equity Grant: Options to purchase 20,001 shares of common stock.
- Exercise Price: $8.57 per share, reflecting the market price on the grant date.
Investor Verification Checklist
- Verify the effective date of the leadership transition (August 1, 2017).
- Review the full text of the Amended and Restated Employment Agreement (Exhibit 10.1) for additional terms not summarized in the filing.
- Confirm the impact of the CFO transition on ongoing financial reporting and audit processes.
- Monitor future filings for any changes in the Company's financial outlook resulting from this personnel change.